Itron, Inc. (ITRI) Tops Q2 EPS by 18c

Itron, Inc. (NASDAQ: ITRI) reported Q2 EPS of $0.54, $0.18 better than the analyst estimate of $0.36. Revenue for the quarter came in at $489 million versus the consensus estimate of $465.61 million.

Twelve-month backlog of $675 million and total backlog of $1.3 billion.

Itron, Inc. sees FY2014 EPS of $1.50-$1.80, versus the consensus of $1.6. Itron, Inc. sees FY2014 revenue of $1.9-1.975 billion, versus the consensus of $1.91 billion.

For earnings history and earnings-related data on Itron, Inc. (ITRI) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Tenon Medical (TNON) Misses Q2 EPS by 395c